title: Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
authors.forename: D M
authors.initials: DM
authors.lastname: Gujral
authors.forename: G
authors.initials: G
authors.lastname: Lloyd
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharyya
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D000068878:Trastuzumab; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human